FORTIS Q2 FY27 Results & Earnings Analysis
Sentiment: Neutral (Confidence: medium)
Earnings Summary
Fortis Healthcare reported a strong quarter with consolidated revenue growing 17.3% YoY to INR 2,735 crores and EBITDA margin expanding by 30 bps to 24.2%, led by its hospital business. The company is on an aggressive expansion path, planning to add ~2,200 beds over the next 3-5 years with a CAPEX of INR 3,500 crore. However, the outlook is tempered by significant regulatory headwinds from new drug price caps, which have led management to project flat margins for FY'27 and withhold guidance for FY'28. While the long-term margin target of 25% for FY'29 is maintained, it is contingent on mitigating these regulatory impacts. The diagnostics business showed volume growth but at a slower pace than peers, with management targeting mid-teens growth in the medium term. The company's balance sheet remains healthy with a net debt-to-EBITDA of 0.87x, and it is well-positioned for future growth, supported by internal accruals and potential capital from its parent, IHH .
Management Tone
- Prepared Remarks: Good — The prepared remarks were confident, highlighting strong performance with revenue growth of 17.3% YoY, improving EBITDA margins, and continued network expansion through acquisitions and partnerships .
- Q&A Session: Neutral — The Q&A tone was neutral and cautious. Management was pressed on margin sustainability, regulatory headwinds from drug price caps, and the rationale for smaller hospital acquisitions. While they provided direct answers, they deferred guidance on future margins and the quantum of the regulatory impac
Revenue Growth Drivers
- Strong performance in key medical specialties and improved case mix
- Network expansion through acquisitions (e.g., Suguna Hospital) and brownfield additions
- Increase in patient volume across hospitals and diagnostics
Growth vs Margin Focus
The company is actively pursuing growth through significant bed capacity expansion (~2,200 beds) and acquisitions . At the same time, management is focused on profitability, as evidenced by their attempts to improve margins and their explicit longer-term FY'29 margin target of 25%, even as they navi
About Fortis Healthcare Limited
Fortis Healthcare Limited (FORTIS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.